Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation

AR Harrington, EP Armstrong, PE Nolan Jr, DC Malone - Stroke, 2013 - Am Heart Assoc
Background and Purpose—To estimate the cost-effectiveness of stroke prevention in
patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg …

[PDF][PDF] Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

DC Malone - 2013 - academia.edu
Background and Purpose—To estimate the cost-effectiveness of stroke prevention in
patients with nonvalvular atrial fibrilla tion by using novel oral anticoagulants apixaban 5 mg …

[引用][C] Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

AR HARRINGTON, EP ARMSTRONG… - Stroke …, 2013 - pascal-francis.inist.fr
Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke
Prevention in Atrial Fibrillation CNRS Inist Pascal-Francis CNRS Pascal and Francis …

Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation

AR Harrington, EP Armstrong, PE Nolan Jr… - Stroke, 2013 - pubmed.ncbi.nlm.nih.gov
Background and purpose To estimate the cost-effectiveness of stroke prevention in patients
with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg …

Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.

AR Harrington, EP Armstrong, PE Nolan Jr, DC Malone - Stroke, 2013 - europepmc.org
Background and purpose To estimate the cost-effectiveness of stroke prevention in patients
with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg …

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

AR Harrington, EP Armstrong, PE Nolan, DC Malone - Stroke, 2013 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Background and Purpose—</jats: title>< jats: p> To estimate the
cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using …

[PDF][PDF] Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

DC Malone - 2013 - med.unipmn.it
Background and Purpose—To estimate the cost-effectiveness of stroke prevention in
patients with nonvalvular atrial fibrilla tion by using novel oral anticoagulants apixaban 5 mg …

[PDF][PDF] Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

DC Malone - Stroke, 2013 - Citeseer
Background and Purpose—To estimate the cost-effectiveness of stroke prevention in
patients with nonvalvular atrial fibrilla tion by using novel oral anticoagulants apixaban 5 mg …

[PDF][PDF] Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

DC Malone - 2013 - scholar.archive.org
Background and Purpose—To estimate the cost-effectiveness of stroke prevention in
patients with nonvalvular atrial fibrilla tion by using novel oral anticoagulants apixaban 5 mg …

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

DC Malone - 2013 - Am Heart Assoc
Background and Purpose—To estimate the cost-effectiveness of stroke prevention in
patients with nonvalvular atrial fibrilla tion by using novel oral anticoagulants apixaban 5 mg …